<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03184155</url>
  </required_header>
  <id_info>
    <org_study_id>17D.172</org_study_id>
    <nct_id>NCT03184155</nct_id>
  </id_info>
  <brief_title>Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine</brief_title>
  <official_title>Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center double blind, placebo controlled study of patients undergoing a
      cardiac catheterization where the need for a percutaneous coronary intervention (PCI) is
      anticipated or will be determined during the early diagnostic phase. The study will assess
      the use of intracoronary nicardipine vs. sterile saline injection in reducing the index
      measurement of microcirculatory resistance (IMR). Fifty consecutive patients presenting to
      the Thomas Jefferson University (TJUH) Cardiac Catheterization lab will be randomized in a
      1:1 fashion to receive either intracoronary nicardipine or sterile saline injection prior to
      PCI. IMR values will be assessed pre and post procedure. Data on clinical outcomes and
      adverse events will be collected by phone at 30 days and 1 year following the procedure.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized double blind, placebo controlled, study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Index of Microcirculatory Resistance (IMR)</measure>
    <time_frame>From the start of the PCI procedure to immediately following the PCI procedure</time_frame>
    <description>IMR is an intracoronary artery pressure measurement obtained during cardiac catheterization, and is a reliable indicator of microvascular dysfunction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-Procedure myocardial Infarction (PMI)</measure>
    <time_frame>6-8 hours post procedure</time_frame>
    <description>PMI is diagnosed by elevation of serum Troponin, 5 times the upper limit following a procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Procedure myocardial Infarction (PMI)</measure>
    <time_frame>12-18 hours post procedure</time_frame>
    <description>PMI is diagnosed by elevation of serum Troponin, 5 times the upper limit following a procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Event</measure>
    <time_frame>30 Days following procedure</time_frame>
    <description>Incidence of myocardial infarction, rehospitalization, or mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Event</measure>
    <time_frame>I year following procedure</time_frame>
    <description>Incidence of myocardial infarction, rehospitalization, or mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Intracoronary Nicardipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mcg intracoronary injection of nicardipine prior to PCI, with potential for additional 100 mcg nicardipine before stent placement, balloon post-dilation, and before post-PCI IMR measurement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection of sterile saline prior to PCI, with potential for additional saline injections before stent placement, balloon post-dilation, and before post-PCI IMR measurement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicardipine</intervention_name>
    <description>200 mcg intracoronary nicardipine injection prior to PCI followed by an additional 2-4 doses of 100 mcg intracoronary nicardipine depending on complexity of PCI</description>
    <arm_group_label>Intracoronary Nicardipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile Saline</intervention_name>
    <description>Bolus of intracoronary sterile saline injection prior to PCI followed by an additional 2-4 doses of sterile saline depending on complexity of PCI</description>
    <arm_group_label>Sterile Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consenting adults age &gt; 18 years

          -  Patients with stable coronary disease, stable angina, and/or objective evidence of
             myocardial ischemia OR

          -  Target vessel lesion with &gt; 50% stenosis treated by PCI

        Exclusion Criteria:

          -  Patients presenting with ST elevation myocardial infarction

          -  Complete total occlusion of the vessel

          -  Unprotected left main disease

          -  Presentation with acute coronary syndrome and actively rising troponin

          -  Contraindication to adenosine (advanced heart blocks, bronchospasm, HSN to the drug)

          -  Known hypersensitivity to nicardipine

          -  Severe aortic stenosis

          -  Left Ventricular dysfunction with ejection fraction less than 30%

          -  Hemodynamically unstable defined as systolic blood pressure &lt; 90 mmHg and not
             responding to IV fluids

          -  Significant chronic renal insufficiency (Glomerular filtration rate [GFR] &lt;30)

          -  Unwilling or unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Savage, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa McCarey, MPH</last_name>
    <phone>215-503-7417</phone>
    <email>melissa.mccarey@jefferson.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Salerno, RN</last_name>
    <phone>215-503-8954</phone>
    <email>thomas.salerno@jefferson.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa McCarey, MPH</last_name>
      <phone>215-503-7417</phone>
      <email>melissa.mccarey@jefferson.edu</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Salerno, RN</last_name>
      <phone>215-503-8954</phone>
      <email>thomas.salerno@jefferson.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nicardipine</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicardipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

